TP53 in MDS and AML: Biological and clinical advances

被引：5
作者：
Zhao, Yeqian [1 ,2 ,3 ,4 ]
Chen, Weihao [1 ]
Yu, Jing [5 ]
Pei, Shanshan [1 ,2 ,3 ,4 ]
Zhang, Qiang [6 ]
Shi, Jimin [1 ,2 ,3 ]
Huang, He [1 ,2 ,3 ]
Zhao, Yanmin [1 ,2 ,3 ]
机构：
[1] Zhejiang Univ, Affiliated Hosp 1, Sch Med, Bone Marrow Transplantat Ctr, Hangzhou 310009, Peoples R China
[2] Zhejiang Univ, Med Ctr, Liangzhu Lab, Hangzhou 311121, Peoples R China
[3] Zhejiang Univ, Inst Hematol, Hangzhou, Peoples R China
[4] Zhejiang Prov Engn Lab Stem Cell & Immun Therapy, Hangzhou, Peoples R China
[5] Zhejiang Univ, Sch Med, Hangzhou, Peoples R China
[6] Zhejiang Jianfeng Grp Co Ltd, Jinhua, Peoples R China
来源：
CANCER LETTERS | 2024年 / 588卷
基金：
中国国家自然科学基金;
关键词：
TP53; mutations; Malignant progression; Multi; -hit; VAF; Prognosis; Treatment; ACUTE MYELOID-LEUKEMIA; CLONAL HEMATOPOIESIS; MUTANT P53; MUTATIONS; EVOLUTION; ABNORMALITIES; AZACITIDINE; VENETOCLAX; FREQUENCY; DELETION;
D O I：
10.1016/j.canlet.2024.216767
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Recently, the WHO -5 and the ICC 2022 criteria have emphasized poor prognosis in AML/MDS patients with multi -hit TP53 mutations, whereas mutated TP53 plays a critical role in tumorigenesis, drawing substantial interest in exploring its biological behaviors. Diverse characteristics of TP53 mutations, including types, VAF, CNVs, allelic status, karyotypes, and concurrent mutations have been extensively studied. Novel potential targets and comprehensive treatment strategies nowadays are under swift development, owing to great advances in technology. However, accurately predicting prognosis of patients with TP53 -mutated myeloid neoplasms remains challenging. And there is still a lack of effective treatment for those patients.
引用
收藏
页数：10
相关论文
共 89 条
  • [1] Genomic landscape of TP53-mutated myeloid malignancies
    Abel, Haley J.
    Oetjen, Karolyn A.
    Miller, Christopher A.
    Ramakrishnan, Sai M.
    Day, Ryan B.
    Helton, Nichole M.
    Fronick, Catrina C.
    Fulton, Robert S.
    Heath, Sharon E.
    Tarnawsky, Stefan P.
    Srivatsan, Sridhar Nonavinkere
    Duncavage, Eric J.
    Schroeder, Molly C.
    Payton, Jacqueline E.
    Spencer, David H.
    Walter, Matthew J.
    Westervelt, Peter
    Dipersio, John F.
    Ley, Timothy J.
    Link, Daniel C.
    [J]. BLOOD ADVANCES, 2023, 7 (16) : 4586 - 4598
  • [2] Venetoclax and hypomethylating agents in TP53-mutated acute myeloid leukaemia
    Aldoss, Ibrahim
    Zhang, Jianying
    Pillai, Raju
    Shouse, Geoffrey
    Sanchez, James F.
    Mei, Matthew
    Nakamura, Ryotaro
    Stein, Anthony S.
    Forman, Stephen J.
    Marcucci, Guido
    Pullarkat, Vinod
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (02) : E45 - E48
  • [3] Results of the Phase I Trial of RG7112, a Small-Molecule MDM2 Antagonist in Leukemia
    Andreeff, Michael
    Kelly, Kevin R.
    Yee, Karen
    Assouline, Sarit
    Strair, Roger
    Popplewell, Leslie
    Bowen, David
    Martinelli, Giovanni
    Drummond, Mark W.
    Vyas, Paresh
    Kirschbaum, Mark
    Iyer, Swaminathan Padmanabhan
    Ruvolo, Vivian
    Gonzalez, Graciela M. Nogueras
    Huang, Xuelin
    Chen, Gong
    Graves, Bradford
    Blotner, Steven
    Bridge, Peter
    Jukofsky, Lori
    Middleton, Steve
    Reckner, Monica
    Rueger, Ruediger
    Zhi, Jianguo
    Nichols, Gwen
    Kojima, Kensuke
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (04) : 868 - 876
  • [4] PPM1D suppresses p53-dependent transactivation and cell death by inhibiting the Integrated Stress Response
    Andrysik, Zdenek
    Sullivan, Kelly D.
    Kieft, Jeffrey S.
    Espinosa, Joaquin M.
    [J]. NATURE COMMUNICATIONS, 2022, 13 (01)
  • [5] International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert P.
    Borowitz, Michael J.
    Calvo, Katherine R.
    Kvasnicka, Hans-Michael
    Wang, Sa A.
    Bagg, Adam
    Barbui, Tiziano
    Branford, Susan
    Bueso-Ramos, Carlos E.
    Cortes, Jorge E.
    Dal Cin, Paola
    DiNardo, Courtney D.
    Dombret, Herve
    Duncavage, Eric J.
    Ebert, Benjamin L.
    Estey, Elihu H.
    Facchetti, Fabio
    Foucar, Kathryn
    Gangat, Naseema
    Gianelli, Umberto
    Godley, Lucy A.
    Gokbuget, Nicola
    Gotlib, Jason
    Hellstrom-Lindberg, Eva
    Hobbs, Gabriela S.
    Hoffman, Ronald
    Jabbour, Elias J.
    Kiladjian, Jean-Jacques
    Larson, Richard A.
    Le Beau, Michelle M.
    Loh, Mignon L. -C.
    Lowenberg, Bob
    Macintyre, Elizabeth
    Malcovati, Luca
    Mullighan, Charles G.
    Niemeyer, Charlotte
    Odenike, Olatoyosi M.
    Ogawa, Seishi
    Orfao, Alberto
    Papaemmanuil, Elli
    Passamonti, Francesco
    Porkka, Kimmo
    Pui, Ching-Hon
    Radich, Jerald P.
    Reiter, Andreas
    Rozman, Maria
    Rudelius, Martina
    Savona, Michael R.
    [J]. BLOOD, 2022, 140 (11) : 1200 - 1228
  • [6] Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm
    Bauer, Matthias R.
    Kraemer, Andreas
    Settanni, Giovanni
    Jones, Rhiannon N.
    Ni, Xiaomin
    Tareque, Raysa Khan
    Fersht, Alan R.
    Spencer, John
    Joerger, Andreas C.
    [J]. ACS CHEMICAL BIOLOGY, 2020, 15 (03) : 657 - 668
  • [7] p53 contains large unstructured regions in its native state
    Bell, S
    Klein, C
    Müller, L
    Hansen, S
    Buchner, J
    [J]. JOURNAL OF MOLECULAR BIOLOGY, 2002, 322 (05) : 917 - 927
  • [8] Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
    Bernard, Elsa
    Nannya, Yasuhito
    Hasserjian, Robert P.
    Devlin, Sean M.
    Tuechler, Heinz
    Medina-Martinez, Juan S.
    Yoshizato, Tetsuichi
    Shiozawa, Yusuke
    Saiki, Ryunosuke
    Malcovati, Luca
    Levine, Max F.
    Arango, Juan E.
    Zhou, Yangyu
    Sole, Francesc
    Cargo, Catherine A.
    Haase, Detlef
    Creignou, Maria
    Germing, Ulrich
    Zhang, Yanming
    Gundem, Gunes
    Sarian, Araxe
    van de Loosdrecht, Arjan A.
    Jadersten, Martin
    Tobiasson, Magnus
    Kosmider, Olivier
    Follo, Matilde Y.
    Thol, Felicitas
    Pinheiro, Ronald F.
    Santini, Valeria
    Kotsianidis, Ioannis
    Boultwood, Jacqueline
    Santos, Fabio P. S.
    Schanz, Julie
    Kasahara, Senji
    Ishikawa, Takayuki
    Tsurumi, Hisashi
    Takaori-Kondo, Akifumi
    Kiguchi, Toru
    Polprasert, Chantana
    Bennett, John M.
    Klimek, Virginia M.
    Savona, Michael R.
    Belickova, Monika
    Ganster, Christina
    Palomo, Laura
    Sanz, Guillermo
    Ades, Lionel
    Della Porta, Matteo Giovanni
    Smith, Alexandra G.
    Werner, Yesenia
    [J]. NATURE MEDICINE, 2020, 26 (10) : 1549 - +
  • [9] A dominant-negative effect drives selection of TP53 missense mutations in myeloid malignancies
    Boettcher, Steffen
    Miller, Peter G.
    Sharma, Rohan
    McConkey, Marie
    Leventhal, Matthew
    Krivtsov, Andrei V.
    Giacomelli, Andrew O.
    Wong, Waihay
    Kim, Jesi
    Chao, Sherry
    Kurppa, Kari J.
    Yang, Xiaoping
    Milenkowic, Kirsten
    Piccioni, Federica
    Root, David E.
    Ruecker, Frank G.
    Flamand, Yael
    Neuberg, Donna
    Lindsley, R. Coleman
    Janne, Pasi A.
    Hahn, William C.
    Jacks, Tyler
    Doehner, Hartmut
    Armstrong, Scott A.
    Ebert, Benjamin L.
    [J]. SCIENCE, 2019, 365 (6453) : 599 - +
  • [10] Clonal Hematopoiesis of Indeterminate Potential
    Boettcher, Steffen
    Ebert, Benjamin L.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (05) : 419 - +
123456789